Coiled Therapeutics plc AIM:COIL
- Incorporated
- United Kingdom
- Chief executive
- Ajan Reginald
- Employees
- 5
- Reports in
- GBP
- Companies House
- 12819145
Read straight from the annual reports
7.3p at close on 5 Oct 2026 · 2 reported years, 2024–2025
| Line | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|
| Revenue | |||
| Operating profit | |||
| Net finance cost | |||
| Profit before tax | |||
| Tax charge | |||
| Profit for the year | |||
| EBITDA | |||
| Basic EPS | |||
| Diluted EPS | |||
| Dividend per share | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
2 years, at a glance
C000309-AR-2025-ch
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
No revenue generated in FY2025 or FY2024; company is pre-revenue/pre-clinical
Revenue £nil (2024: £nil); Directors' Report states principal activity was preclinical development
page 4075% reduction in salaries and Directors' fees implemented August 2024, maintained through 2025
Administrative expenses decreased to £683,653 (2024: £931,642) mainly due to Directors' and employee costs reducing to £41,146 (2024: £397,659)
page 15Impairment of intangible assets (Lyramid and MK Cell programmes)
Impairment charge of £2,486,944 recognised in the year following loss of recoverability of Lyramid and MK Cell assets
page 40£1.2m charge: Impairment of Lyramid (Midkine antibody) intangible assets following termination of third-party licence agreement
page 62Coiled Therapeutics has a clear lead asset in AO-252, a defined clinical strategy and is well funded to reach a series of key milestones; the Board expects comprehensive data readouts from ovarian and prostate cancer expansion cohorts in H2 2026, which represent the most significant near-term value catalyst.
page 527 March 2026: Company completed acquisition of exclusive worldwide licence to AO-252 from Coiled Therapeutics, Inc. (a spin-out of A2A Pharmaceuticals, Inc.) for upfront consideration of approximately £31.875 million satisfied by issue of new ordinary shares; up to 750 million further shares issuable as deferred consideration contingent on market cap thresholds of £60m/£90m/£120m; plus milestone payments up to US$12 million and royalties up to 4% on net sales
page 74The Directors do not propose a dividend in respect of the year ended 31 December 2025 (no dividend in 2024 either)
page 9Audit opinion unqualified/unmodified (true and fair view); going concern was a key audit matter but no material uncertainty identified — auditors verified receipt of the post-year-end £8.5m gross (~£7.7m net) fundraise completed 27 March 2026 as part of AIM admission, which materially changed the Group's liquidity position (prior year audit report had included a material uncertainty re going concern). Auditor: RPG Crouch Chapman LLP (Paul Randall FCA, Senior Statutory Auditor), signed 5 May 2026. Other KAMs: carrying value of intangible assets and impairment (£2,486,944 impairment charge), carrying value of investments, management override of controls.
page 33- Group is not break-even and there is no guarantee it will generate significant profits in the near future; pre-revenue business riskp.16
- Research and development risks carry technical risks including delays, failure of third-party suppliers, and outcomes of clinical testing; no guarantee of successful, approved productp.16
- Biotechnology programmes subject to stringent regulatory oversight; trials may be suspended/abandoned; no guarantee of regulatory approval even if efficaciousp.17
- No guarantee of securing appropriate licensing deal or alternative commercialisation means even where technically/regulatorily successfulp.17
Read from C000309-AR-2025-ch.
1 annual report read
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (1)
FY2026Next report expected 12 May 2027